

Patient Name: **SMITH, JOHN**

 Specimen Number: **C22-000349**

Patient Rec. #:

Alliance ID:

Date of Birth: 02/02/1962

Age: 60

Ordering Client: THE BEST DOCTOR

Sex: Male

Ordering Physician: THE BEST DOCTOR

Date Collected: 12/26/22

Client Address: 7200 W Camino Real, Suite 330

Date Received: 12/26/22

Boca Raton, FL 33433

Date Reported: 12/27/22

Telephone: (561) 453-1234

Fax: (561) 453-1238

CC Physician:

CYTOLOGY REPORT


SMITH, JOHN
INTERPRETATION

Specimen #: C22-000349

HIGH GRADE UROTHELIAL CARCINOMA

The specimen exhibits malignant cells consistent with high grade urothelial carcinoma.

Date: 12/26/22



MICROSCOPIC DESCRIPTION Isolated malignant cells demonstrate high nuclear-to-cytoplasmic ratio, marked nuclear hyperchromasia, coarse chromatin, irregular nuclei.

SOURCE OF SPECIMEN Voided Urine

GROSS DESCRIPTION Received 80 ml of yellow clear fluid in PreservCyt fixative, labeled with patient's name and a second identifier. One liquid-based slide (F50) prepared. A urine Aptima tube was prepared for CT/GC molecular testing. Half of the specimen is submitted for Bladder Cancer FISH testing. (2 CellSolutions F50: PAPx1, FISHx1)

CLINICAL HISTORY Malignant neoplasm of bladder

ADDITIONAL TESTS

- 1) C. trachomatis RNA, TMA: NOT DETECTED
- 2) N. gonorrhoeae RNA, TMA: NOT DETECTED

The CT/GC assay were performed using the Aptima Combo 2(R) Assay. The analytical performance characteristics of these assay, when used to test Aptima(R) have been determined by Alliance laboratories of South East Florida, tested on 12/27/2022. Methodology: Transcription Mediated Amplification (TMA)

NOTES Bladder Cancer FISH test result to follow

SCREENED BY:

Woosung Park, CT(ASCP)

Electronically REVIEWED BY: Mercedes Ficarra, MD. Board Certified in Pathology/Cytopathology

Date: 12/27/2022 Time: 13:38:06

CPT CODES

88112

_____ **END OF REPORT** _____